Growth hormone cocktail improves hepatopulmonary syndrome secondary to hypopituitarism: A case report

Table 1 Hormone, respiratory data, and hepatitis B screening on admission

Hormone data	Value	Respiratory data	Value	HBV serologic testing	Value
TSH (0.380-4.340 μU/mL)	4.595	FVC	3.15 L	HBsAg	-
FT3 (1.80-4.10 pg/mL)	1.62	%VC	55%	HBsAb	-
FT4 (0.81-1.89 pg/mL)	4.05	FEV1.0	2.63L	HBeAg	-
GH (< 2.0 ng/mL)	< 0.05	FEV1.0%	84%	HBeAb	-
IGF-1 (ng/mL)	32 (115-307)	%DLCO	36.5%	HBcAb	-
ACTH (8 am, pg/mL)	10.3
Cortisol (8 am, 4.26-24.85 μg/dL)	20.06
FSH (1.27-19.26 U/L)	0.35
LH (1.24-8.62 U/L)	0.21
Testosterone (1.75-7.81 ng/mL)	< 0.1
Estradiol (< 47 pg/mL)	6.8
Progesterone (0.10-0.84 ng/mL)	< 0.08
Prolactin (2.6-13.1 ng/mL)	14.18

TSH: Thyroid stimulating hormone; FT3: Free triiodothyronine; FT4: Free thyroxine; ACTH: Adrenocorticotropic hormone; FSH: Follicle stimulating hormone; LH: Luteinizing hormone; FVC: Forced vital capacity; VC: Vital capacity; FEV: Forced expiratory volume; DLCO: Diffusing capacity of the lung for carbon monoxide; HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody; HBeAg: Hepatitis B e antibody; HBeAb: Hepatitis B e antibody; HBcAb: Hepatitis B core antibody; -: Negative.